
CLAIMS

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt or a stereoisomer thereof;

wherein,

ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl;

ring B is aryl, cycloalkyl, heterocyclyl or absent;






$R_1$ is hydrogen or alkyl;

$R_2$ is hydrogen, alkyl or cycloalkyl;

$R_3$ is hydrogen, alkyl or heteroaryl;

alternatively, $R_2$ together with $R_1$ or $R_3$ along with the ring atoms to which they are attached forms a 5-7 membered ring;

$R_4$ at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;

$R_5$ is , , ,  or ; wherein $R_5'$ is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or $-(CH_2)_{1-3}-NR_aR_b$; $R_5''$ is H or alkyl;

$R_a$ and $R_b$ are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl; alternatively, $R_a$ and $R_b$ together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, alkyl,

acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or –COO-alkyl;

$R_6$ at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;

$L_1$ is *–$CR_cR_d$-C(O)–, *–$NR_eC(O)$– or absent; wherein * is point of attachment with ring A;

$R_c$ and $R_d$ independently are hydrogen, alkyl or haloalkyl; alternatively, $R_c$ and $R_d$ together with the carbon atom to which they are attached form a cycloalkyl ring;

$R_e$ is hydrogen or alkyl;


$L_2$ is –C(O)NH–, –C(O)O- or absent;

m is 0, 1 or 2;

p is 0 or 1; and

q is 0 to 3.

2. The compound of claim 1, having a compound of formula (IA):




(IA)

or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;

wherein,

ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl;

ring B is aryl, cycloalkyl, heterocyclyl or absent;






$R_1$ is hydrogen or alkyl;

$R_2$ is hydrogen, alkyl or cycloalkyl;

$R_3$ is hydrogen, alkyl or heteroaryl;

alternatively, $R_2$ together with $R_1$ or $R_3$ along with the ring atoms to which they are attached forms a 5-7 membered ring;

$R_4$ at each occurrence is halo, alkyl, hydroxy or alkoxy;

$R_5$ is , , ,  or ; wherein $R_5'$ is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or $-(CH_2)_{1-3}-NR_aR_b$; $R_5''$ is H or alkyl;

$R_a$ and $R_b$ are each independently hydrogen or alkyl; alternatively, $R_a$ and $R_b$ together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, alkyl, hydroxy, haloalkyl or alkoxy;

$L_1$ is *–$CR_cR_d$-C(O)–, *–$NR_eC(O)$– or absent; wherein * is point of attachment with ring A;

$R_c$ and $R_d$ independently are hydrogen, alkyl or haloalkyl; alternatively, $R_c$ and $R_d$ together with the carbon atom to which they are attached form a cycloalkyl ring;


$R_e$ is hydrogen or alkyl;

$L_2$ is –C(O)NH–, –C(O)O- or absent;

m is 0, 1 or 2; and

p is 0 or 1.


3. The compound of claim 1, having a compound of formula (IB):



(IB)

or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.


4. The compound of claim 1, having a compound of formula (IC):




(IC)

or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.


5. The compound of claim 1, having a compound of formula (ID):




(ID)

or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

6. The compound of claim 1, having a compound of formula (IE):





(IE)

or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;

wherein, $L_1$ is *–$CR_cR_d$-C(O)– or *–$NR_eC(O)$–; wherein * is point of attachment with phenyl.

7. The compound of claim 1, having a compound of formula (IF):




(IF)

or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;

wherein, $L_1$ is *–$CR_cR_d$-C(O)– or *–$NR_eC(O)$–; wherein * is point of attachment with phenyl.

8. The compound of claim 1, having a compound of formula (IG):



(IG)


or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

9. The compound of claim 1, wherein ring A is aryl or heteroaryl.

10. The compound according to any one of claims 1 to 5, wherein ring B is monocyclic or bicyclic cycloalkyl, aryl, heterocycloalkyl or heteroaryl.

11. The compound according to any one of claims 1 to 5, wherein $R_2$ is cycloalkyl.

12. The compound according to any one of claims 1 to 8, wherein $R_5$ is



13. The compound according to claim_12, wherein $R_5'$ is $-(CH_2)_{1-3}-NR_aR_b$.

14. The compound according to any one of claims 12 or 13, wherein $R_a$ and $R_b$ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring having 0-2 additional heteroatoms selected from O, S or N.

15. The compound according to any one of claims 1 to 8, wherein $L_1$ is *–$CR_cR_d$-C(O)–; wherein * is the point of attachment with ring A.

16. The compound according to any one of claims 1 to 3, wherein $L_2$ is *–C(O)NH– or*–C(O)O-; wherein * is the point of attachment with ring B.

17. A compound selected from:

| Compound No. | IUPAC name |
|---|---|
| 1 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 2 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide (Isomer-1 of compound-1); |
| 3 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide (Isomer-2 of compound-1); |
| 4 | (E)-N-(5'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-2'-fluoro-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 5 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-4'-fluoro-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |

| | |
|---|---|
| 6 | (E)-N-(3'-(1-((5-cyclopropyl-1-methyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 7 | (E)-N-(3'-(2-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-2-oxoethyl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 8 | (E)-4-(dimethylamino)-N-(3'-(1-((5-ethyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)but-2-enamide; |
| 9 | (E)-N-(3'-(1-((5-(tert-butyl)-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 10 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide; |
| 11 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide (Isomer-1 of compound-10); |
| 12 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide (Isomer-2 of compound-10); |
| 13 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxobutan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 14 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 15 | (E)-N-(3'-(1-((5-cyclobutyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 16 | (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-3-yl)-4-(dimethylamino)but-2-enamide; |
| 17 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-2-fluoro-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 18 | N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)acrylamide; |

| | |
|---|---|
| 19 | N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-yl)acrylamide; |
| 20 | N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide; |
| 21 | N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide (Isomer-1 of compound-20); |
| 22 | N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide (Isomer-2 of compound-20); |
| 23 | N-(5'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-2',3-difluoro-[1,1'-biphenyl]-4-yl)acrylamide; |
| 24 | N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-3-yl)acrylamide; |
| 25 | 2-(4'-acrylamido-3'-fluoro-[1,1'-biphenyl]-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-methylbutanamide; |
| 26 | 2-(3-(5-acrylamidopyridin-2-yl)phenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)butanamide; |
| 27 | 2-(4'-acrylamido-3'-fluoro-[1,1'-biphenyl]-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)butanamide; |
| 28 | (E)-N-(3'-(1-((5-cyclopentyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 29 | (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(1-(4-(dimethylamino)but-2-enoyl)indolin-5-yl)phenyl)propanamide; |
| 30 | N-(3'-(1-((5-cyclopropyl-4-methyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)acrylamide; |
| 31 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxobutan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 32 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-yl)-4-(diethylamino)but-2-enamide; |

| | |
|---|---|
| 33 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-yl)-4-(pyrrolidin-1-yl)but-2-enamide; |
| 34 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-yl)-4-morpholinobut-2-enamide; |
| 35 | (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-3-yl)-4-morpholinobut-2-enamide; |
| 36 | (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-3-yl)-4-(dimethylamino)but-2-enamide; |
| 37 | (E)-4-((6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-3-yl)amino)-N,N-dimethylbut-2-enamide; |
| 38 | (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-2-fluoropyridin-3-yl)-4-(dimethylamino)but-2-enamide; |
| 39 | (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-3-yl)-4-(piperidin-1-yl)but-2-enamide; |
| 40 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(piperidin-1-yl)but-2-enamide; |
| 41 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-methoxybut-2-enamide; |
| 42 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(dimethylamino)but-2-enamide; |
| 43 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 44 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide; |
| 45 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(3-fluoropyrrolidin-1-yl)but-2-enamide; |
| 46 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2- |

| | |
|---|---|
| | enamide; |
| 47 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2-enamide (Isomer-1 of compound-46); |
| 48 | E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2-enamide (Isomer-2 of compound-46); |
| 49 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((R)-3-fluoropyrrolidin-1-yl)but-2-enamide |
| 50 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((R)-3-fluoropyrrolidin-1-yl)but-2-enamide (Isomer-1 of compound-49); |
| 51 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((R)-3-fluoropyrrolidin-1-yl)but-2-enamide (Isomer-2 of compound-49); |
| 52 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide; |
| 53 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide (Isomer-1 of compound-52); |
| 54 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide (Isomer-2 of compound-52); |
| 55 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(diethylamino)but-2-enamide; |
| 56 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-(dimethylamino)but-2-enamide; |

| | |
|---|---|
| 57 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(3-fluoropiperidin-1-yl)but-2-enamide; |
| 58 | (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-2-fluoropyridin-3-yl)-4-morpholinobut-2-enamide; |
| 59 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-6-fluoropyridin-2-yl)-4-morpholinobut-2-enamide; |
| 60 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-3-yl)-4-morpholinobut-2-enamide; |
| 61 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-3-yl)-4-morpholinobut-2-enamide; |
| 62 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(methoxy(methyl)amino)but-2-enamide; |
| 63 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-3-fluoropyridin-2-yl)-4-morpholinobut-2-enamide; |
| 64 | (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-2-fluoropyridin-3-yl)-4-(3-fluoropyrrolidin-1-yl)but-2-enamide; |
| 65 | N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-methoxy-[1,1'-biphenyl]-4-yl)acrylamide; |
| 66 | N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-methyl-[1,1'-biphenyl]-4-yl)acrylamide; |
| 67 | N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3,5-dimethyl-[1,1'-biphenyl]-4-yl)acrylamide; |
| 68 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((2-methoxyethyl)(methyl)amino)but-2-enamide; |
| 69 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(1H-imidazol-1-yl)but-2-enamide; |

| | |
|---|---|
| 70 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((S)-2-(methoxymethyl)pyrrolidin-1-yl)but-2-enamide; |
| 71 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((S)-2-(methoxymethyl)pyrrolidin-1-yl)but-2-enamide (Isomer-1 of compound-70); |
| 72 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((S)-2-(methoxymethyl)pyrrolidin-1-yl)but-2-enamide (Isomer-2 of compound-70); |
| 73 | N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-2-methoxy-[1,1'-biphenyl]-4-yl)acrylamide; |
| 74 | N-((5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)methyl)acrylamide; |
| 75 | N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-2-methyl-[1,1'-biphenyl]-4-yl)acrylamide; |
| 76 | 2-(3-(1-acryloylindolin-5-yl)phenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide; |
| 77 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((2S,4S)-4-fluoro-2-(methoxymethyl)pyrrolidin-1-yl)but-2-enamide; |
| 78 | (E)-4-(3-cyanopyrrolidin-1-yl)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2-enamide; |
| 79 | N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyrazin-2-yl)acrylamide; |
| 80 | (E)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2-enamide; |
| 81 | methyl ((E)-4-((5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1- |

| | |
|---|---|
| | oxopropan-2-yl)phenyl)pyridin-2-yl)amino)-4-oxobut-2-en-1-yl)-L-prolinate; |
| 82 | (E)-4-((S)-2-(cyanomethyl)pyrrolidin-1-yl)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2-enamide; |
| 83 | 4-acrylamido-N-(3-((5-ethyl-1H-pyrazol-3-yl)amino)phenyl)benzamide; |
| 84 | (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(1-(4-(dimethylamino)but-2-enoyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)propanamide; |
| 85 | (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(1-(4-(dimethylamino)but-2-enoyl)piperidin-4-yl)phenyl)propanamide; |
| 86 | N-(3'-(2-((5-methyl-1H-pyrazol-3-yl)amino)-2-oxoethyl)-[1,1'-biphenyl]-4-yl)acrylamide; |
| 87 | N-(3'-(1-((5-ethyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)acrylamide; |
| 88 | N-(3'-(1-((5-(tert-butyl)-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)acrylamide; |
| 89 | (E)-N-(3-((1H-indazol-3-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide; |
| 90 | N-(3'-(1-((1H-indazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)acrylamide; |
| 91 | (E)-N-(3'-(1-((1H-indazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 92 | (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyrazin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide; |
| 93 | (S,E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide; |

| | |
|---|---|
| 94 | (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-1-(3-(6-(4-(pyrrolidin-1-yl)but-2-enamido)pyridin-3-yl)phenyl)cyclopropane-1-carboxamide; |
| 95 | (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-2-methyl-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide; |
| 96 | (*E*)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide; |
| 97 | (*E*)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-(3-fluoropyrrolidin-1-yl)but-2-enamide; |
| 98 | (*E*)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-(3-hydroxypyrrolidin-1-yl)but-2-enamide; |
| 99 | (*E*)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-(piperidin-1-yl)but-2-enamide; |
| 100 | (*E*)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-(3-fluoropiperidin-1-yl)but-2-enamide; |
| 101 | (*E*)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-(3-hydroxypiperidin-1-yl)but-2-enamide; |
| 102 | (*E*)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-(4-fluoropiperidin-1-yl)but-2-enamide; |
| 103 | (*E*)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-(4-hydroxy-4-methylpiperidin-1-yl)but-2-enamide; |
| 104 | (*E*)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-(4,4-difluoropiperidin-1-yl)but- |


| | |
|---|---|
| | 2-enamide; |
| 105 | (*E*)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-(diethylamino)but-2-enamide; |
| 106 | (*E*)-N-(1-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)piperidin-4-yl)-4-(dimethylamino)but-2-enamide; |
| 107 | (*E*)-N-(3-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-1-methyl-1H-pyrazol-5-yl)-4-(dimethylamino)but-2-enamide; |
| 108 | (*E*)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(4-(4-(dimethylamino)but-2-enoyl)piperazin-1-yl)phenyl)propanamide; |
| 109 | 3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl (E)-4-(4-(dimethylamino)but-2-enoyl)piperazine-1-carboxylate; |
| 110 | (*E*)-4-((S)-2-cyanopyrrolidin-1-yl)-N-(5-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2-enamide; |
| 111 | (*E*)-4-((2S,4S)-2-(cyanomethyl)-4-fluoropyrrolidin-1-yl)-N-(5-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2-enamide; |
| 112 | (*E*)-N-(3'-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-yl)-4-((S)-2-(methoxymethyl)pyrrolidin-1-yl)but-2-enamide; |
| 113 | (*E*)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4-(4-(dimethylamino)but-2-enoyl)morpholine-2-carboxamide; |
| 114 | (*E*)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4-(4-(dimethylamino)but-2-enamido)tetrahydro-2H-pyran-3-carboxamide; |


| | |
|---|---|
| 115 | (*E*)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidine-2-carboxamide; |
| 116 | (*E*)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-1-(4-(dimethylamino)but-2-enoyl)piperidine-2-carboxamide; |
| 117 | (*E*)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-1-(4-(dimethylamino)but-2-enoyl)piperidine-3-carboxamide; |
| 118 | (*E*)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4-(dimethylamino)but-2-enamide; |
| 119 | (*E*)-N-(4-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4-(dimethylamino)but-2-enamide; |
| 120 | (*E*)-N-(2-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4-(dimethylamino)but-2-enamide; |
| 121 | 2-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl (E)-4-(4-(dimethylamino)but-2-enoyl)piperazine-1-carboxylate; |
| 122 | 4-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl (E)-4-(4-(dimethylamino)but-2-enoyl)piperazine-1-carboxylate; |
| 123 | (*E*)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-6-fluoropyridin-2-yl)-4-(dimethylamino)but-2-enamide; |
| 124 | (*E*)-N-(3-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-4-yl)-4-morpholinobut-2-enamide; |
| 125 | (*E*)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-2-yl)-4-morpholinobut-2-enamide; |
| 126 | (*E*)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4-(4-(dimethylamino)but-2-enoyl)piperazine-1- |


| | |
|---|---|
| | carboxamide; |
| 127 | (*E*)-N-(6-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2-enamide; |
| 128 | (*E*)-N-(6-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyrazin-2-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2-enamide; |
| 129 | (*E*)-N-(5-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-((S)-3-(trifluoromethyl)pyrrolidin-1-yl)but-2-enamide; |
| 130 | (*E*)-4-((2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl)-N-(5-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2-enamide; |
| 131 | (*E*)-4-((S)-2-cyanopyrrolidin-1-yl)-N-(5-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2-enamide; |
| 132 | (*S,E*)-N-(3'-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-yl)-4-(diethylamino)but-2-enamide; |
| 133 | (*E*)-N-(4-(3-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-4-methylisoquinolin-6-yl)phenyl)-4-(dimethylamino)but-2-enamide; and |
| 134 | (*E*)-N-(4-(4-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)pyridin-2-yl)phenyl)-4-(dimethylamino)but-2-enamide; |
| 135 | (*E*)-N-(4-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)cyclohexyl)-4-(dimethylamino)but-2-enamide; |
| 136 | (*E*)-N-(3-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)cyclohexyl)-4-(dimethylamino)but-2-enamide; |
| 137 | (*E*)-4-(dimethylamino)-N-(3'-(1-oxo-1-(pyrazolo[1,5-a]pyridin-2-ylamino)propan-2-yl)-[1,1'-biphenyl]-4-yl)but-2-enamide; |


| | |
|---|---|
| 138 | (*E*)-N-(3'-(3-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1,1,1-trifluoro-3-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 139 | (*E*)-N-(3'-(1-((5-cyclopentyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 140 | (*E*)-N-(3'-(1-((5-cyclohexyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 141 | (*E*)-N-(3'-(1-((5-cyclopropyl-4-methyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |
| 142 | (*E*)-N-(3'-(1-((5-cyclopropyl-4-(pyridin-2-yl)-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; and |
| 143 | (*E*)-N-(3'-(3-(5-cyclopropyl-1H-pyrazol-3-yl)-1-methylureido)-[1,1'-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; |


or a pharmaceutically acceptable salt or a stereoisomer thereof.


18. A compound of formula:  (Compound 46) or a pharmaceutically acceptable salt or a stereoisomer thereof.


19. A compound of formula:  (Compound 47) or a pharmaceutically acceptable salt or a stereoisomer thereof.


20. A compound of formula:  (Compound 20) or a pharmaceutically acceptable salt or a stereoisomer thereof.


21. A compound of formula:  (Compound 22) or a pharmaceutically acceptable salt or a stereoisomer thereof.


22. A compound of formula:  (Compound 44) or a pharmaceutically acceptable salt or a stereoisomer thereof.


23. A compound of formula:  (Compound 10) or a pharmaceutically acceptable salt or a stereoisomer thereof.


24. A compound of formula:  (Compound 12) or a pharmaceutically acceptable salt or a stereoisomer thereof.


25. A compound of formula:  (Compound 52) or a pharmaceutically acceptable salt or a stereoisomer thereof.

26. A compound of formula:  (Compound 54) or a pharmaceutically acceptable salt or a stereoisomer thereof.

27. A compound of formula:  (Compound 56) or a pharmaceutically acceptable salt or a stereoisomer thereof.

28. A compound of formula:  (Compound 40) or a pharmaceutically acceptable salt or a stereoisomer thereof.

29. A compound of formula:  (Compound 43) or a pharmaceutically acceptable salt or a stereoisomer thereof.

30. A compound of formula:  (Compound 57) or a pharmaceutically acceptable salt or a stereoisomer thereof.

31. A pharmaceutical composition comprising a compound of any one of claims 1 to 30, or a pharmaceutically acceptable salt or a stereoisomer thereof and at least one pharmaceutically acceptable excipient.

32. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt or a stereoisomer thereof, for use in the treatment of cancer.

33. A pharmaceutical composition according to claim 31 for use in treating a subject suffering from diseases and/or disorder associated with aberrant activity of selective transcriptional CDKs.

34. A pharmaceutical composition according to claim 31 for use in treating a subject suffering from diseases and/or disorder associated with aberrant activity of transcriptional CDK9, CDK12, CDK13 or CDK18.

35. A pharmaceutical composition according to claim 31 for use in treating a subject suffering from diseases and/or disorder_associated with aberrant activity of transcriptional CDK7.

36. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt or a stereoisomer thereof, for use in inhibiting selective transcriptional CDKs in a subject.

37. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt or a stereoisomer thereof, for use in treating diseases and/or disorders mediated by selective transcriptional CDKs in a subject.

38. A compound or a pharmaceutically acceptable salt or a stereoisomer thereof for use according to claim 37, wherein the diseases and/or disorders mediated by selective transcriptional CDKs is selected from the group consisting of a cancer, an inflammatory disorder, an auto-inflammatory disorder and an infectious disease.

39. A compound or a pharmaceutically acceptable salt or a stereoisomer thereof for use according to claim 38, wherein the cancer is selected from the group consisting of a carcinoma, including that of the breast, liver, lung, colon, kidney, bladder, including small cell lung cancer, non-small cell lung cancer, head and neck, thyroid, esophagus, stomach, pancreas, ovary, gall bladder, cervix, prostate and skin,

including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia, Hodgkins lymphoma, non-Hodgkins lymphoma, B-cell lymphoma, T- cell lymphoma, hairy cell lymphoma, myeloma, mantle cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of masenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; and other tumors, including seminoma, melanoma, osteosarcoma, teratocarcinoma, keratoctanthoma, xenoderoma pigmentosum, thyroid follicular cancer and Kaposi's sarcoma.

40. A compound or a pharmaceutically acceptable salt or a stereoisomer thereof for use according to any one of claims 36 to 39, wherein the selective transcriptional CDKs are CDK7, CDK9, CDK12, CDK13 or CDK 18.

41. Use of a compound of any one of claims 1 to 30 in the manufacture of a medicament for the treatment of cancer.

42. Use of a pharmaceutical composition according to claim 31 in the manufacture of a medicament for treating a subject suffering from diseases and/or disorder associated with aberrant activity of selective transcriptional CDKs.

43. Use of a pharmaceutical composition according to claim 31, in the manufacture of a medicament for treating a subject suffering from diseases and/or disorder associated with aberrant activity of transcriptional CDK9, CDK12, CDK13 or CDK18.

44. Use of a pharmaceutical composition according to claim 31, in the manufacture of a medicament for treating a subject suffering from diseases and/or disorder associated with aberrant activity of transcriptional CDK7.

45. Use of a compound of any one of claims 1 to 30, in the manufacture of a medicament for inhibiting selective transcriptional CDKs in a subject.

46. Use of a compound of any one of claims 1 to 30, in the manufacture of a medicament for treating diseases and/or disorders mediated by selective transcriptional CDKs in a subject.

47. Use according to claim 46, wherein the diseases and/or disorders mediated by selective transcriptional CDKs is selected from the group consisting of a cancer, an inflammatory disorder, an auto-inflammatory disorder and an infectious disease.

48. Use according to claim 47, wherein the cancer is selected from the group consisting of a carcinoma, including that of the breast, liver, lung, colon, kidney, bladder, including small cell lung cancer, non-small cell lung cancer, head and neck, thyroid, esophagus, stomach, pancreas, ovary, gall bladder, cervix, prostate and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia, Hodgkins lymphoma, non-Hodgkins lymphoma, B-cell lymphoma, T- cell lymphoma, hairy cell lymphoma, myeloma, mantle cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of masenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; and other tumors, including seminoma, melanoma, osteosarcoma,

teratocarcinoma, keratoctanthoma, xenoderoma pigmentosum, thyroid follicular cancer and Kaposi's sarcoma.

49. Use according to any one of claims 45 to 48, wherein the selective transcriptional CDKs are CDK7, CDK9, CDK12, CDK13 or CDK 18.